Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

被引：0
作者：
Vitale, Pasquale [1 ]
De Falco, Vincenzo [1 ]
Addeo, Raffaele [1 ,2 ]
机构：
[1] Hosp Frattamaggiore, Oncol Operat Unit, Frattamaggiore, Italy
[2] ASLNA2NORD, San Giovanni Dio Hosp, Oncol Operat Unit, Via D Pirozzi 62, I-80027 Frattamaggiore, NA, Italy
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2024年 / 24卷 / 07期
关键词：
Recurrent/metastatic head and neck cancer; cetuximab; PD-L1; pembrolizumab; chemotherapy; combined positive score; SQUAMOUS-CELL CARCINOMA; CHEMOTHERAPY PLUS CETUXIMAB; RECURRENT; PEMBROLIZUMAB; KEYNOTE-048;
D O I：
10.1080/14737140.2024.2354772
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：481 / 484
页数：4
相关论文
共 24 条
  • [1] CheckMate 141 trial: all that glitters is not gold
    Addeo, Raffaele
    Ghiani, Massimo
    Merlino, Francesco
    Ricciardiello, Filippo
    Caraglia, Michele
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (03) : 169 - 171
  • [2] Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma
    Barsouk, Adam
    Aluru, John Sukumar
    Rawla, Prashanth
    Saginala, Kalyan
    Barsouk, Alexander
    [J]. MEDICAL SCIENCES, 2023, 11 (02)
  • [3] BROWMAN GP, 1994, SEMIN ONCOL, V21, P311
  • [4] Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
    Burtness, Barbara
    Rischin, Danny
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    de Castro Jr, Gilberto
    Psyrri, Amanda
    Brana, Irene
    Baste, Neus
    Neupane, Prakash
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett G. M.
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Wan Ishak, Wan Zamaniah
    Ge, Joy
    Swaby, Ramona F.
    Gumuscu, Burak
    Harrington, Kevin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (21) : 2321 - +
  • [5] Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
    Burtness, Barbara
    Harrington, Kevin J.
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    de Castro, Gilberto, Jr.
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett G. M.
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Hong, Ruey-Long
    Mendoza, Rene Gonzalez
    Roy, Ananya
    Zhang, Yayan
    Gumuscu, Burak
    Cheng, Jonathan D.
    Jin, Fan
    Rischin, Danny
    [J]. LANCET, 2019, 394 (10212) : 1915 - 1928
  • [6] Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
    Chen, Tien-Hua
    Pan, Yi-Ying
    Lee, Tsung-Lun
    Wang, Ling-Wei
    Tai, Shyh-Kuan
    Chu, Pen-Yuan
    Lo, Wen-Liang
    Wu, Cheng-Hsien
    Yang, Muh-Hwa
    Chang, Peter Mu-Hsin
    [J]. BMC CANCER, 2022, 22 (01)
  • [7] Head and Neck Cancer
    Chow, Laura Q. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01) : 60 - 72
  • [8] Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
    Cohen, Ezra E. W.
    Soulieres, Denis
    Le Tourneau, Christophe
    Dinis, Jose
    Licitra, Lisa
    Ahn, Myung-Ju
    Soria, Ainara
    Machiels, Jean-Pascal
    Mach, Nicolas
    Mehra, Ranee
    Burtness, Barbara
    Zhang, Pingye
    Cheng, Jonathan
    Swaby, Ramona F.
    Harrington, Kevin J.
    [J]. LANCET, 2019, 393 (10167) : 156 - 167
  • [9] Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
    De Keukeleire, Stijn Jeroen
    Vermassen, Tijl
    Deron, Philippe
    Huvenne, Wouter
    Duprez, Frederic
    Creytens, David
    Van Dorpe, Jo
    Ferdinande, Liesbeth
    Rottey, Sylvie
    [J]. CANCERS, 2022, 14 (10)
  • [10] Immunotherapy for head and neck cancer: Present and future
    Fasano, Morena
    Della Corte, Carminia Maria
    Di Liello, Raimondo
    Viscardi, Giuseppe
    Sparano, Francesca
    Iacovino, Maria Lucia
    Paragliola, Fernando
    Piccolo, Antonio
    Napolitano, Stefania
    Martini, Giulia
    Morgillo, Floriana
    Cappabianca, Salvatore
    Ciardiello, Fortunato
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 174
123